IMPACT OF NEUROTROPIC VIRUSES ON SURVIVAL OF PATIENTS WITH SURGICALLY TREATED GLIOBLASTOMA.
antibodies
brain neoplasms
cytomegalovirus
glioblastoma
herpes simplex
Journal
Acta clinica Croatica
ISSN: 1333-9451
Titre abrégé: Acta Clin Croat
Pays: Croatia
ID NLM: 9425483
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
24
05
2021
accepted:
11
06
2021
medline:
27
7
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
Glioblastoma represents the most aggressive tumor of the brain with an estimated survival rate of twelve to fifteen months after the primary diagnosis. The role of neurotropic viruses in pathogenesis of the tumor has remained unclear to date. During the last two decades, many studies were conducted with the aim of confirming viral influence in the development of glioblastoma. We conducted a retrospective study in a time period of five years using formalin-fixed paraffin-embedded tissues of glioblastoma. Immunohistochemistry was performed for three viruses: CMV, EBV and HSV-1, using an automated staining system. Mean age of patients in our group was 66.7±8.5 years. A slight male dominance was noted. Negative immunohistochemistry results were obtained for CMV and EBV, which were excluded from further investigation. Based on IRS score, we confirmed six HSV-1 samples which were rated as IRS score 2. Five more samples of HSV-1 were rated as IRS score 1 and were excluded from the study. According to our retrospective study and its results, we found no impact of neurotropic viruses in the survival rate of glioblastoma. Further studies should be conducted including a wider range of viral detection methods.
Identifiants
pubmed: 37492371
doi: 10.20471/acc.2022.61.03.12
pii: acc-61-476
pmc: PMC10364100
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-481Déclaration de conflit d'intérêts
Conflict of interests: None.
Références
Acta Neuropathol. 2006 Apr;111(4):388-96
pubmed: 16557392
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Neuro Oncol. 2014 Apr;16(4):513-9
pubmed: 24305701
PLoS One. 2015 Jan 21;10(1):e114989
pubmed: 25608026
J Virol. 2012 Jan;86(2):854-64
pubmed: 22090104
Clin Cancer Res. 2017 Jun 15;23(12):3150-3157
pubmed: 28034905
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Acta Neuropathol. 2008 Jul;116(1):79-86
pubmed: 18351367
Pharmacol Ther. 2015 Aug;152:63-82
pubmed: 25944528
In Vivo. 2017 Mar-Apr;31(2):221-229
pubmed: 28358704
Mod Pathol. 2014 Jul;27(7):922-9
pubmed: 24336154
J Virol. 2013 Oct;87(19):10477-88
pubmed: 23903843
Int J Mol Sci. 2020 Jul 16;21(14):
pubmed: 32708697
Mod Pathol. 2005 Jun;18(6):838-43
pubmed: 15578071
Am J Epidemiol. 2001 Jul 15;154(2):161-5
pubmed: 11447050
Int J Cancer. 2015 Feb 15;136(4):977-81
pubmed: 24961996
Int Rev Immunol. 2014 Jul-Aug;33(4):266-83
pubmed: 24266364
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Med Clin (Barc). 2009 Jul 4;133(5):196-7
pubmed: 19268982
Clin Microbiol Rev. 2014 Oct;27(4):691-726
pubmed: 25278572
Cancer Res. 2001 May 15;61(10):4287-93
pubmed: 11358858
Case Rep Med. 2009;2009:757898
pubmed: 20029672
J Neurovirol. 2011 Dec;17(6):512-7
pubmed: 22052379
Cancer Res. 2002 Jun 15;62(12):3347-50
pubmed: 12067971
Acta Clin Croat. 2022 Feb;60(3):373-378
pubmed: 35282478
Int J Exp Pathol. 2001 Jun;82(3):149-70
pubmed: 11488990
Acta Neuropathol. 2005 Jan;109(1):93-108
pubmed: 15685439